LAM Pilot Study with Imatinib LAMP-2

Abstract

This pilot trial employs a dual agent design intended to generate safety and efficacy data sufficient to power and design a longer-term trial of imatinib in the treatment of LAM. The hypothesis is that imatinib can be safely co-administered with sirolimus and will result in change in serum biomarkers of LAM. Durability of response will not be tested. Importantly, the widely established LAM biomarker of disease activity, VEGF-D will be used in this small clinical trial design using 20 participants. The there specific aims are: Specific Aim 1: To determine the safety and tolerability of Imatinib in the treatment of LAM. Specific Aim 2: To determine the safety and tolerability of concurrent imatinib and sirolimus treatment in LAM. Specific Aim 3: To evaluate the effect of imatinib treatment on serum biomarkers of LAM.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2023
Accession Number
AD1216892

Entities

People

  • Jeanine M. D'Armiento

Organizations

  • Columbia University

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cancer
  • Carcinoma
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Colon Cancer
  • Endoplasmic Reticulum
  • Epithelial Cells
  • Health Services
  • Information Science
  • Lymphatic Diseases
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Rna Sequence Analysis

Fields of Study

  • Medicine

Readers

  • Aquatic Ecology
  • Molecular and Cellular Biology
  • Neurotrauma and Rehabilitation Medicine.